I’m sure Howie would make a good CEO for any biopharma company with his track record and associations, but the extra attraction of keeping him on for any buyer would be his knowledge and expertise in BOT’s pipeline of products, not just SB. Do you think any buyer would just be happy to let all BOT senior management just walk away after any purchase of the company? That’s not usually how it works.
Ann: Notification regarding unquoted securities - BOT, page-18
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $640.6M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 36.0¢ | 34.8¢ | $1.003M | 2.851M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 761160 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 38682 | 3 |
View Market Depth
| Last trade - 11.37am 17/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |